Assessment of Efficacy of AZD2281 in Platinum Sensitive Serous Ovarian Cancer
Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Astra Zeneca
250 participants
Aug 30, 2008
Interventional
Conditions
Summary
The primary purpose of the study is to determine the efficacy of the study drug AZD2281 compared to placebo by looking at progression free survival of the patients. Progression will be determined by tumour assessments and evaluations and patients will have regular imaging scans. The study hypotheses that AZD2281 given after an objective stable maintained response on completion of platinum containing chemotherapy improves progression free survival compared to placebo in platinum sensitive serous advanced ovarian cancer patients who have previously received two or platinum containing regimens.
Eligibility
Inclusion Criteria4
- Female patients with histologically diagnosed serous ovarian cancer or recurrent serous ovarian cancer.
- Patients must have completed at least 2 previous courses of platinum containing therapy; the patient must have been platinum sensitive to the previous 2 chemo regimens.
- For the last chemotherapy course prior to enrolment on the study, patients must have demonstrated an objective stable maintained response (partial or complete response) and this response needs to be maintained until completion of chemotherapy.
- Patients must be treated on the study within 8 wks of completion of their final dose of the platinum containing regimen.
Exclusion Criteria4
- Previous treatment with polyadenosine 5’-diphosphoribose polymerase (PARP) inhibitors including AZD2281
- Patients with low grade ovarian carcinoma.
- Patients who have had drainage of their ascites during the final 2 cycles of their last chemotherapy regimen prior to enrolment on the study
- Patients receiving any chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study entry (or a longer period depending on the defined characteristics of the agents used).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
AZD2281 or Olaparib is a potent inhibitor of polyadenosine 5’-diphosphoribose polymerase (PARP) that is being developed as an oral treatment for patients with BRCA (Breast Cancer Gene Type) related cancer. The molecular targeting of olaparib to specific subsets of tumours may provide an opportunity for less toxic cancer monotherapy and adjuvant therapy, compared with currently available regimen. In this study, AZD2281 will be given orally 400mg twice daily. Participants will be receiving AZD2281 till their tumour assessment (via imaging scans) show disease progression according to the protocol. They can chose to stop participating in the study and hence stop receiving the drug. Their doctors or the sponsor may also stop them from receiving the study drug if it was discovered that patient is at risk, non-compliant, or for other reasons.
Locations(9)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000159257